fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Mefloquine HCL

All products: not a benefit

Lariam · DIN 02018055 · 250 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2013-05-02 — choose a marketed DIN from the same-category list.Discontinued May 2, 2013 · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2013-05-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-05-02 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Lariam · DIN 02018055 Manufacturer: Hoffmann-La Roche Limited; listing date 2007-06-06 Health Canada: Cancelled post market since 2013-05-02 · brand LARIAM TAB 250MG · ATC P01BC02 MEFLOQUINE · form Tablet · route Oral · ingredients MEFLOQUINE (MEFLOQUINE HYDROCHLORIDE) 250 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lariam: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02018055)

Source record
DIN 02018055: Lariam Raw flags: sec3=Y, sec3b=Y Item: 082000011; group id 121; item number 0204; lccId None; manufacturer id HLR Source form: Tab; strength: 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02018055 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13721
Interchangeable products
Mefloquine · DIN 02244366 · $3.6950
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02018055
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 2, 2013 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (P01B): coverage varies; not interchangeable

  • Hydroxychloroquine (Plaquenil): general benefit
  • Atovaquone + proguanil (Malarone): not a benefit
Other drugs in the same formulary class (08:20 Plasmodicides (Antimalarials)) and how they are covered

Matched class: 08:20 Plasmodicides (Antimalarials)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: HYDROXYCHLOROQUINE SULFATE 08:20 Plasmodicides (Antimalarials)

HYDROXYCHLOROQUINE SULFATE

· 6 products · General benefit · strengths: 200mg · Tab

ATOVAQUONE & PROGUANIL HCL

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg & 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:20
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: prophylaxis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. WARFARIN · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) • Prophylaxis and/or treatment of venous thrombosis and its extension, PM: https://pdf.hres.ca/dpd_pm/00084195.PDF; date 2026-04-08; DIN 02242680; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS MEFLOQUINE (mefloquine tablets) is indicated for: • Prophylaxis: Prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum. • Treatment of Acute Malaria Infections: Treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine- susceptible and resistant strains) or by P. vivax. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of mefloquine tablets in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use. See 7.1.3 Pediatrics. Experience with mefloquine in infants less than 3 months old or weighing less than 5 kg is limited. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience is limited in this age group. Use in the geriatric population may be associated with differences in safety or effectiveness. See 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00080420.PDF PM date: MAY 01, 2025 Source product: MEFLOQUINE; DIN 02244366; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Lariam: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026